Idioma:

Assessing the global availability of misoprostol

Fernandez, Maria M ; Coeytaux, Francine ; Gomez Ponce de León, Rodolfo ; Harrison, Denise L

International journal of gynecology and obstetrics, 2009-05, Vol.105 (2), p.180-186 [Periódico revisado por pares]

Shannon: Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Assessing the global availability of misoprostol
Autor: Fernandez, Maria M ; Coeytaux, Francine ; Gomez Ponce de León, Rodolfo ; Harrison, Denise L
Assuntos: Abortifacient Agents, Nonsteroidal - economics ; Abortifacient Agents, Nonsteroidal - supply & distribution ; Biological and medical sciences ; Birth control ; Delivery. Postpartum. Lactation ; Digestive system ; Drug approval ; Drug prices ; Gynecology. Andrology. Obstetrics ; Health Services Accessibility - trends ; Induced abortion. Therapeutic abortion ; Internationality ; Maternal mortality ; Medical sciences ; Misoprostol ; Misoprostol - economics ; Misoprostol - supply & distribution ; Obstetric-gynecologic indications ; Obstetrics - trends ; Obstetrics and Gynecology ; Pharmacology. Drug treatments ; Postpartum hemorrhage ; Reproductive health ; Termination of pregnancy
É parte de: International journal of gynecology and obstetrics, 2009-05, Vol.105 (2), p.180-186
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Abstract Objective To assess the worldwide availability of misoprostol. Documenting the extent of misoprostol use in obstetrics-gynecology is difficult because the drug typically is unregistered for such indications. Methods Data for 2002–2007 on annual sales (measured in weight) to hospitals and retail pharmacies, plus manufacturer prices per 200-µg misoprostol, were analyzed for medications containing misoprostol alone or combined with a nonsteroidal anti-inflammatory drug (NSAID); regional and country-specific trends were identified. Consumer prices per pill are documented for all formulations of registered medications. Results Of the misoprostol sold worldwide, 70% was misoprostol-NSAID-combination drugs; of this, 91% was sold in North America and Western Europe. Asia sold the most misoprostol-only drugs; sales increased dramatically in Bangladesh (by 128%) and India (646%), where various low-price brands are sold. Misoprostol sales decreased in Latin America but increased in the Middle East-North Africa and Sub-Saharan Africa; these regions generally had low amounts sold per population. Conclusion Availability is improving in some low-income regions where misoprostol could significantly reduce maternal deaths due to postpartum hemorrhage and unsafe abortion.
Editor: Shannon: Elsevier Ireland Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Assessing the global availability of misoprostol

Fernandez, Maria M ; Coeytaux, Francine ; Gomez Ponce de León, Rodolfo ; Harrison, Denise L

Shannon: Elsevier Ireland Ltd

Buscando em bases de dados remotas. Favor aguardar.